Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NEUROBLASTOMA”

770 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 770 results

Testing effectiveness (Phase 2)Looking for participantsNCT07100704
What this trial is testing

Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab

Who this might be right for
Recurrent/ Metastatic Olfactory Neuroblastoma
National Cancer Center Hospital East 14
Early research (Phase 1)Active Not RecruitingNCT02311621
What this trial is testing

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

Who this might be right for
NeuroblastomaGanglioneuroblastoma
Seattle Children's Hospital 65
Testing effectiveness (Phase 2)WithdrawnNCT02011126
What this trial is testing

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Who this might be right for
HepatoblastomaPreviously Treated Childhood RhabdomyosarcomaRecurrent Childhood Liver Cancer+5 more
Children's Oncology Group
Early research (Phase 1)UnknownNCT02013336
What this trial is testing

Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

Who this might be right for
Recurrent or Refractory Solid TumorsEwing SarcomaRhabdomyosarcoma+2 more
South Plains Oncology Consortium 30
Not applicableAvailableNCT06872489
What this trial is testing

Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors

Who this might be right for
Neuroblastoma in ChildrenNeuroblastoma, Recurrent, RefractoryAdvanced Cancer+7 more
Second Life Therapeutics
Large-scale testing (Phase 3)Looking for participantsNCT06071897
What this trial is testing

Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma

Who this might be right for
NeuroblastomaGanglioneuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 15
Testing effectiveness (Phase 2)Looking for participantsNCT02559778
What this trial is testing

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Who this might be right for
Neuroblastoma
Giselle Sholler 500
Testing effectiveness (Phase 2)Study completedNCT00135135
What this trial is testing

Therapy for Children With Neuroblastoma

Who this might be right for
Neuroblastoma
St. Jude Children's Research Hospital 23
Testing effectiveness (Phase 2)UnknownNCT01807468
What this trial is testing

Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors

Who this might be right for
NeuroblastomaEwing SarcomaRhabdomyosarcoma+2 more
Samsung Medical Center 12
Early research (Phase 1)Study completedNCT01222780
What this trial is testing

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

Who this might be right for
SarcomaNeuroblastomaWilms Tumor+3 more
Acrotech Biopharma Inc. 22
Early research (Phase 1)Ended earlyNCT00053950
What this trial is testing

Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma

Who this might be right for
Disseminated NeuroblastomaRecurrent Neuroblastoma
National Cancer Institute (NCI) 42
Not applicableStudy completedNCT05245123
What this trial is testing

Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families

Who this might be right for
NeuroblastomaNephroblastomaHepatoblastoma
Universitätsklinikum Hamburg-Eppendorf 100
Early research (Phase 1)Study completedNCT00877110
What this trial is testing

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Who this might be right for
NeuroblastomaBone Marrow, Sympathetic Nervous System
Memorial Sloan Kettering Cancer Center 71
Early research (Phase 1)WithdrawnNCT01130623
What this trial is testing

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

Who this might be right for
SarcomaNeuroblastomaWilms Tumor+2 more
National Cancer Institute (NCI)
Not applicableLooking for participantsNCT00588068
What this trial is testing

Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center 2,070
Testing effectiveness (Phase 2)UnknownNCT00416559
What this trial is testing

Observation of Young Patients With Localized Neuroblastoma Who Have Undergone Surgery Only

Who this might be right for
Long-term Effects Secondary to Cancer Therapy in ChildrenNeuroblastoma
Children's Cancer and Leukaemia Group 140
Testing effectiveness (Phase 2)Active Not RecruitingNCT02650401
What this trial is testing

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Who this might be right for
Solid TumorsCNS Tumors
Hoffmann-La Roche 69
Early research (Phase 1)Study completedNCT01059071
What this trial is testing

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Who this might be right for
Neuroblastoma
Giselle Sholler 21
Testing effectiveness (Phase 2)Looking for participantsNCT06607692
What this trial is testing

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Who this might be right for
Solid Tumor CancerMedulloblastomaHigh Risk Neuroblastoma+19 more
Fundación de investigación HM 25
Testing effectiveness (Phase 2)Looking for participantsNCT07537400
What this trial is testing

Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

Who this might be right for
High-Risk Neuroblastoma
Shaare Zedek Medical Center 10
Next Page